Literature DB >> 11072080

Molecular cloning and characterization of the human dihydropyrimidine dehydrogenase promoter.

S A Shestopal1, M R Johnson, R B Diasio.   

Abstract

Several studies have demonstrated that dihydropyrimidine dehydrogenase (EC 1.3.1.2) has a critical role in the pharmacokinetics of the anticancer agent 5-fluorouracil. We previously reported the structural organization of the human DPYD gene. In this article, we describe the molecular cloning and functional characterization of 1.2 kb of the 5' flanking region of the DPYD gene. Sequence analysis demonstrated that this region of the DPYD gene lacks the typical TATA or CCAAT boxes with several GC-rich regions containing potential cis-regulatory elements. Progressive 5' deletions of the 5' flanking region were fused to the luciferase reporter gene and transient expression measured following transfection into HeLa and 293 cells. Comparative analysis of luciferase activity revealed that a 208 bp region of the DPYD gene (-121/+86) contained equivalent transcriptional activity to the complete 1.2 kb 5' flanking region of the DPYD gene. Site-directed mutagenesis of the luciferase reporter constructs demonstrated that the -72/-23 sequence contained two regulatory regions (designated elements I and II) essential for promoter activity. Gel shift experiments demonstrated that both regulatory elements specifically bind with protein(s) from nuclear extracts of 293 cells. Competitive binding experiments with 293 nuclear extracts and radiolabeled oligonucleotides (corresponding to elements I and II) suggest that the same protein(s) bind to both regulatory elements. We conclude that constitutive expression of the DPYD gene involves a limited GC-rich region of the 5' flanking sequence of the DPYD gene which contains two regulatory elements.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11072080     DOI: 10.1016/s0167-4781(00)00213-x

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

1.  Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences.

Authors:  Keiko Maekawa; Mayumi Saeki; Yoshiro Saito; Shogo Ozawa; Kouichi Kurose; Nahoko Kaniwa; Manabu Kawamoto; Naoyuki Kamatani; Ken Kato; Tetsuya Hamaguchi; Yasuhide Yamada; Kuniaki Shirao; Yasuhiro Shimada; Manabu Muto; Toshihiko Doi; Atsushi Ohtsu; Teruhiko Yoshida; Yasuhiro Matsumura; Nagahiro Saijo; Jun-Ichi Sawada
Journal:  J Hum Genet       Date:  2007-09-09       Impact factor: 3.172

2.  Future prospects of personalized chemotherapy in gastric cancer patients: results of a prospective randomized pilot study.

Authors:  Kazuhiro Yoshida; Kazuaki Tanabe; Hideaki Ueno; Kouji Ohta; Jun Hihara; Tetsuya Toge; Masahiko Nishiyama
Journal:  Gastric Cancer       Date:  2003       Impact factor: 7.370

3.  Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy.

Authors:  Ursula Amstutz; Simone Farese; Stefan Aebi; Carlo R Largiadèr
Journal:  J Exp Clin Cancer Res       Date:  2008-10-20

4.  Integrating precision medicine in the study and clinical treatment of a severely mentally ill person.

Authors:  Jason A O'Rawe; Han Fang; Shawn Rynearson; Reid Robison; Edward S Kiruluta; Gerald Higgins; Karen Eilbeck; Martin G Reese; Gholson J Lyon
Journal:  PeerJ       Date:  2013-10-03       Impact factor: 2.984

5.  Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer.

Authors:  Tetsuro Tominaga; Tomoshi Tsuchiya; Koji Mochinaga; Junichi Arai; Naoya Yamasaki; Keitaro Matsumoto; Takuro Miyazaki; Toshiya Nagasaki; Atsushi Nanashima; Kazuhiro Tsukamoto; Takeshi Nagayasu
Journal:  BMC Cancer       Date:  2016-06-06       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.